To join a ovarian cancer clinical trial in United States, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in United States directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.

What phases are ovarian cancer trials in United States?

Active ovarian cancer trials in United States span EARLY_Phase 1, Phase 1, Phase 1, Phase 2, Phase 2, Phase 3. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.

Browse More

All United States Trials → Global ovarian cancer Trials → All Countries → All Trials →

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology

Active Trials in United States (36)

Using Aspirin to Improve Immunological Features of Ovarian Tumors

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

EXoPERT EMERALD Clinical Study

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

A Beta-only IL-2 ImmunoTherapY Study

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

UNTOLD Ovarian Cancer Unmet Needs Survey

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

Frequently Asked Questions